Quantum Dot‐Based Screening System for Discovery of G Protein‐Coupled Receptor Agonists
- 12 June 2012
- journal article
- research article
- Published by Wiley in ChemBioChem
- Vol. 13 (10) , 1503-1508
Abstract
Cellular imaging has emerged as an important tool to unravel biological complexity and to accelerate the drug‐discovery process, including cell‐based screening, target identification, and mechanism of action studies. Recently, semiconductor nanoparticles known as quantum dots (QDs) have attracted great interest in cellular imaging applications due to their unique photophysical properties such as size, tunable optical property, multiplexing capability, and photostability. Herein, we show that QDs can also be applied to assay development and eventually to high‐throughput/content screening (HTS/HCS) for drug discovery. We have synthesized QDs modified with PEG and primary antibodies to be used as fluorescent probes for a cell‐based HTS system. The G protein‐coupled receptor (GPCR) family is known to be involved in most major diseases. We therefore constructed human osteosarcoma (U2OS) cells that specifically overexpress two types of differently tagged GPCRs: influenza hemagglutinin (HA) peptide‐tagged κ‐opioid receptors (κ‐ORs) and GFP‐tagged A3 adenosine receptors (A3AR). In this study, we have demonstrated that 1) anti‐HA antibody‐conjugated QDs could specifically label HA‐tagged κ‐ORs, 2) subsequent treatment of QD‐tagged GPCR agonists allowed agonist‐induced translocation to be monitored in real time, 3) excellent emission spectral properties of QD permitted the simultaneous detection of two GPCRs in one cell, and 4) the robust imaging capabilities of the QD–antibody conjugates could lead to reproducible quantitative data from high‐content cellular images. These results suggest that the present QD‐based GPCR inhibitor screening system can be a promising platform for further drug screening applications.Keywords
This publication has 31 references indexed in Scilit:
- Endocytosis of nanomedicinesJournal of Controlled Release, 2010
- Targeting SDF-1/CXCL12 with a Ligand That Prevents Activation of CXCR4 through Structure-Based Drug DesignJournal of the American Chemical Society, 2010
- Peptide Kappa Opioid Receptor Ligands: Potential for Drug DevelopmentThe AAPS Journal, 2009
- Assessing GPCR activation using protein complementation: a novel technique for HTSBiochemical Society Transactions, 2007
- k Opioids as potential treatments for stimulant dependenceThe AAPS Journal, 2005
- Quantum dot bioconjugates for imaging, labelling and sensingNature Materials, 2005
- Construction and characterization of a kappa opioid receptor devoid of all free cysteinesProtein Engineering, Design and Selection, 2004
- Classical and new roles of β-arrestins in the regulation of G-PROTEIN-COUPLED receptorsNature Reviews Neuroscience, 2001
- Opioid receptors: past, present and futureTrends in Neurosciences, 1995
- Mis-assembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit formation.Journal of Cell Biology, 1993